From: "Chadwick" <River@wyattdesigngroup.com>
To: <paliourg@iit.demokritos.gr>
Subject:  stock newsletter presents facts without the hype
Date: Wed, 10 Aug 2005 09:49:53 +0300
MIME-Version: 1.0
Content-Type: text/html;
	charset="iso-8859-7"
Content-Transfer-Encoding: quoted-printable
X-Priority: 3
X-MSMail-Priority: Normal
X-MimeOLE: Produced By Microsoft MimeOLE V6.00.2900.2527

<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 3.2//EN">
<HTML>
<HEAD>
<META HTTP-EQUIV=3D"Content-Type" CONTENT=3D"text/html; =
charset=3Dus-ascii">
<META NAME=3D"Generator" CONTENT=3D"MS Exchange Server version =
6.5.7036.0">
<TITLE> stock newsletter presents facts without the =
hype</TITLE>
</HEAD>
<BODY>
<!-- Converted from text/plain format -->

<P><FONT SIZE=3D2>The key to making serious money through investing is =
not to follow the crowd.<BR>
<BR>
Make no mistake: Our mission at SmallCap-Investors is to claw our way =
through<BR>
the thousands of underperforming companies out there to find the golden =
needle<BR>
in the haystack the micro-cap DIAMOND that can make you rich. More often =
than not,<BR>
the stocks we profile show a significant increase in stock price and =
sometimes in days,<BR>
not months or years. We have come across what we feel is one of those =
rear deals<BR>
that the public has not heard about yet.<BR>
<BR>
We Told at 1.20 to WATCH PGCN and now its $2.00 up again today.<BR>
<BR>
Harbin Pingchuan Pharmaceutical: (PGCN)<BR>
Current Price: $2.00<BR>
Shares Outstanding: 20 Million<BR>
Market Capitalization: $6 Million<BR>
Short Term Target: $5.75<BR>
12month Target: $10.00<BR>
Market Performance: STRONG BUY<BR>
<BR>
***NEWS RELEASE***NEWS RELEASE***NEWS RELEASE***NEWS RELEASE***NEWS =
RELEASE***<BR>
<BR>
HARBIN, China, /Xinhua-PRNewswire-FirstCall/ -- Harbin Pingchuan =
Pharmaceutical Holding Co. Ltd.<BR>
(OTC Bulletin Board: PGCN - News; &quot;PINGCHUAN&quot;) announced today =
that PINGCHUAN signed a Purchase Agreement<BR>
with the Guangdong Medicine Group Co. Ltd. (&quot;GDMG&quot;).<BR>
Under the terms of the agreement, PINGCHUAN will authorize GDMG as its =
franchisee<BR>
in five southern provinces of China. With respect to the authorization, =
GDMG intends<BR>
to purchase approximately US$2.00million worth of PINGCHUAN's =
pharmaceutical products in 2005.<BR>
By cooperating with GDMG, PINGCHUAN will greatly enhance the marketing =
network and sales channels<BR>
in Southern China.<BR>
<BR>
&quot;We are delighted to reach this agreement with the leading medical =
enterprise in Southern China.<BR>
This purchase agreement not only increases our sales revenue in these =
five provinces, but also<BR>
substantially improves our brand awareness in Southern China. While =
maintaining the existing<BR>
marketing network, we are developing and setting up new marketing =
network and sales channel actively.&quot;<BR>
Said Hu ZhanWu, Chairman and President of Pingchuan Pharmaceutical Co. =
Ltd., &quot;One of our<BR>
marketing strategies is to establish a connection with medical =
enterprises such as<BR>
Guangdong Medicine Group, for the promotion of our products into their =
commercial networks<BR>
throughout the entire country.&quot;<BR>
<BR>
***<BR>
<BR>
GET PGCN FIRST THING WEDNESDAY, THIS IS GOING TO EXPLODE IN THE NEXT 2-5 =
DAYS.<BR>
<BR>
<BR>
<BR>
<BR>
<BR>
<BR>
<BR>
Disclaimer:<BR>
Information within this email contains &quot;forwardlooking =
statements&quot; within<BR>
the meaning of Section 27Aof the Securities Act of 1933 and Section 21B =
of<BR>
the Securities Exchange Act of 1934. Any statements that express or =
involve<BR>
discussions with respect to predictions, expectations, beliefs,<BR>
plans, projections, objectives, goals, assumptions or future events =
or<BR>
performance are not statements of historical fact and may be =
&quot;forward<BR>
looking statements&quot;. &quot;Forward looking statements&quot; are =
based on<BR>
expectations, estimates and projections at the time the statements are =
made<BR>
that involve a number of risks and uncertainties which could cause =
actual<BR>
results or events to differ materially from those presently =
anticipated.<BR>
Forward looking statements in this action may be identified through the =
use<BR>
of words such as &quot;projects&quot;, &quot;foresee&quot;, =
&quot;expects&quot;, &quot;will&quot;, &quot;anticipates&quot;,<BR>
&quot;estimates&quot;, &quot;believes&quot;, &quot;understands&quot; or =
that by statements indicating<BR>
certain actions &quot;may&quot;, &quot;could&quot;, or &quot;might&quot; =
occur. Risk factors include<BR>
general economic and business conditions, the ability to acquire and =
develop<BR>
specific projects, the ability to fund operations and changes in =
consumer<BR>
and business consumption habits and other factors overwhich the company =
has<BR>
little or no control. The publisher of this newsletter does not =
represent<BR>
that the information contained in this message states all material facts =
or<BR>
does not omit a material fact necessary to make the statements therein =
not<BR>
misleading. All information provided within this email pertaining to<BR>
investing, ST0CKs, securities must be understood as information provided =
and<BR>
not investment advice. The publisher of this newsletter advises all =
readers<BR>
and subscribers to seek advice from a registered professional =
securities<BR>
representative before deciding to trade in ST0CKs featured within =
this<BR>
email. None of the material within this report shall be construed as =
any<BR>
kind of investment advice or solicitation. Many of these companies are =
on<BR>
the verge of bankruptcy. You can lose all your money by investing in =
this<BR>
ST0CK. We urge you to read the company's SEC filings now, before you =
invest.<BR>
The publisher of this newsletter is not a registered invstment =
advisor.<BR>
Subscribers should not view information herein as legal, tax, accounting =
or<BR>
investment advice. In compliance with the SecuritiesAct of 1933, =
Section<BR>
17(b), The publisher of this newsletter is contracted to receive six =
hundred<BR>
thousand free trading shares from a third party, not an officer, =
director or<BR>
affiliate shareholder for the circulation of this report. Be aware of =
an<BR>
inherent conflict of interest resulting from such compensation due to =
the<BR>
fact that this is a paid advertisement and is not without bias. The =
party<BR>
that paid us has a position in the ST0CK they will sell at anytime =
without<BR>
notice. This could have a negative impact on the price of the ST0CK, =
causing<BR>
you to lose money. All factual information in this report was gathered =
from<BR>
public sources, including but not limited to SEC filings, Company =
Websites<BR>
and Company Press Releases. The publisher of this newsletter believes =
this<BR>
information to be reliable but can make no guarantee as to its accuracy =
or<BR>
completeness. Use of the material within this email constitutes your<BR>
acceptance of these terms.<BR>
<BR>
<BR>
<BR>
</FONT>
</P>

</BODY>
</HTML>
